|
EP2990416B1
(en)
|
2014-08-29 |
2018-06-20 |
GEMoaB Monoclonals GmbH |
Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
|
|
US11091546B2
(en)
*
|
2015-04-15 |
2021-08-17 |
The Scripps Research Institute |
Optimized PNE-based chimeric receptor T cell switches and uses thereof
|
|
US11701387B2
(en)
|
2018-01-04 |
2023-07-18 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptor specific for BDCA2 antigen
|
|
WO2019152957A1
(en)
*
|
2018-02-02 |
2019-08-08 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Dna-chimeric antigen receptor t cells for immunotherapy
|
|
EP3775902B1
(en)
|
2018-04-04 |
2023-02-22 |
F. Hoffmann-La Roche AG |
Diagnostic assays to detect tumor antigens in cancer patients
|
|
WO2019195759A1
(en)
*
|
2018-04-05 |
2019-10-10 |
Mayo Foundation For Medical Education And Research |
Materials and methods for treating cancer
|
|
KR20210003780A
(ko)
|
2018-04-05 |
2021-01-12 |
스미토모 다이니폰 파마 온콜로지, 인크. |
Axl 키나제 억제제 및 그의 용도
|
|
WO2019222642A1
(en)
*
|
2018-05-18 |
2019-11-21 |
Senti Biosciences, Inc. |
Engineered immune cells and methods of use
|
|
EP3836944A4
(en)
*
|
2018-08-16 |
2022-05-11 |
Memorial Sloan Kettering Cancer Center |
LEUCINE ZIPPER BASED COMPOSITIONS AND METHODS OF USE
|
|
EP4588483A3
(en)
*
|
2018-10-03 |
2025-09-24 |
University of Pittsburgh- Of the Commonwealth System of Higher Education |
Covalent adaptor synnotch and chimeric antigen receptors (cars) for programmable antigen-targeting
|
|
EP3873540A4
(en)
|
2018-10-31 |
2022-07-27 |
Mayo Foundation for Medical Education and Research |
METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
|
|
WO2020092839A1
(en)
|
2018-10-31 |
2020-05-07 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
CN119752797A
(zh)
*
|
2019-01-22 |
2025-04-04 |
北京大学深圳研究生院 |
天然配体介导的多靶点识别可调控基因工程化免疫细胞的制备方法
|
|
ES3051182T3
(en)
|
2019-01-23 |
2025-12-26 |
Miltenyi Biotec Bv & Co Kg |
A combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject
|
|
WO2020201527A1
(en)
|
2019-04-04 |
2020-10-08 |
Umc Utrecht Holding B.V. |
Modified immune receptor constructs
|
|
CN110151999A
(zh)
*
|
2019-05-22 |
2019-08-23 |
中国人民解放军第四军医大学 |
用于抑制恶性黑色素瘤进展的靶向药物
|
|
CA3142108A1
(en)
|
2019-05-28 |
2020-12-03 |
Miltenyi Biotec B.V. & Co. KG |
Method for generation of genetically modified t cells
|
|
WO2021007580A1
(en)
|
2019-07-11 |
2021-01-14 |
Valkyr, Inc. |
System and methods relating to chimeric autoantibody receptors
|
|
WO2021047804A1
(en)
|
2019-09-11 |
2021-03-18 |
Miltenyi Biotec B.V. & Co. KG |
In vitro method for transduction of t cells in the presence of malignant cells
|
|
JP2023500799A
(ja)
|
2019-10-18 |
2023-01-11 |
トラスティーズ オブ ボストン ユニバーシティ |
Ｃａｌ－ｔコンストラクトおよびその使用
|
|
CN115052887B
(zh)
|
2019-12-11 |
2026-03-31 |
A2生物治疗公司 |
基于lilrb1的嵌合抗原受体
|
|
WO2021143826A1
(zh)
*
|
2020-01-17 |
2021-07-22 |
信达生物制药(苏州)有限公司 |
重组抗程序性死亡受体1和抗分化抗原簇137双特异性抗体制剂及其用途
|
|
CN111234033B
(zh)
*
|
2020-01-21 |
2021-05-11 |
南京北恒生物科技有限公司 |
多链嵌合抗原受体及其用途
|
|
WO2021156277A1
(en)
|
2020-02-04 |
2021-08-12 |
Miltenyi Biotec B.V. & Co. KG |
Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens
|
|
CN115298209A
(zh)
*
|
2020-02-20 |
2022-11-04 |
森迪生物科学公司 |
抑制性嵌合受体构造体
|
|
EP4107175A4
(en)
*
|
2020-02-20 |
2024-03-20 |
Senti Biosciences, Inc. |
ARCHITECTURES OF INHIBITORY CHIMERIC RECEPTORS
|
|
CA3171906A1
(en)
|
2020-03-16 |
2021-09-23 |
University Of Southern California |
Novel antigen binding domains and synthetic antigen receptors incorporating the same
|
|
US20210322471A1
(en)
*
|
2020-03-27 |
2021-10-21 |
Dcprime B.V. |
In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
WO2021226289A2
(en)
*
|
2020-05-05 |
2021-11-11 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using cd70 specific fusion proteins
|
|
WO2021234006A1
(en)
|
2020-05-20 |
2021-11-25 |
Miltenyi Biotec B.V. & Co. KG |
Compositions and methods for treating cancer expressing cd90 and cd326
|
|
US12286465B2
(en)
|
2020-05-28 |
2025-04-29 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains
|
|
EP4171617A1
(en)
|
2020-06-30 |
2023-05-03 |
Mendus B.V. |
Use of leukemia-derived cells in ovarian cancer vaccines
|
|
BR112023003036A2
(pt)
|
2020-08-19 |
2023-04-25 |
Astellas Pharma Inc |
Região fc modificada de ocorrência não natural humana de igg especificamente ligando-se a receptor de fc modificado de ocorrência não natural
|
|
IL300500A
(en)
|
2020-08-20 |
2023-04-01 |
A2 Biotherapeutics Inc |
Preparations and methods for the treatment of mesothelin positive cancer
|
|
CA3188867A1
(en)
|
2020-08-20 |
2022-02-24 |
Xueyin Wang |
Compositions and methods for treating ceacam positive cancers
|
|
WO2022040444A1
(en)
|
2020-08-20 |
2022-02-24 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating egfr positive cancers
|
|
EP4210733B1
(en)
|
2020-09-04 |
2024-11-06 |
Miltenyi Biotec B.V. & Co. KG |
System for inducible expression of an adapter in immune cells
|
|
WO2022081841A1
(en)
*
|
2020-10-16 |
2022-04-21 |
Fred Hutchinson Cancer Research Center |
Specific targeting of tumor-infiltrating regulatory t cells (tregs) using icos and il-1r1
|
|
WO2022096664A1
(en)
|
2020-11-09 |
2022-05-12 |
Miltenyi Biotec B.V. & Co. KG |
Methods and compositions for eliminating engineered immune cells
|
|
JP2024506249A
(ja)
|
2021-01-22 |
2024-02-13 |
メンドゥス・ベスローテン・フェンノートシャップ |
腫瘍ワクチン接種の方法
|
|
WO2023057285A1
(en)
|
2021-10-06 |
2023-04-13 |
Miltenyi Biotec B.V. & Co. KG |
Method for targeted gene insertion into immune cells
|
|
US11819578B2
(en)
|
2021-10-07 |
2023-11-21 |
Trustees Of Boston University |
Nanofiber scaffolds
|
|
WO2023062113A1
(en)
|
2021-10-15 |
2023-04-20 |
Miltenyi Biotec B.V. & Co. KG |
Method for the generation of genetically modified nk cells
|
|
US20250255959A1
(en)
|
2022-04-01 |
2025-08-14 |
Miltenyi Biotec B.V. & Co. KG |
A system for drug-inducible expression of a polynucleotide
|
|
WO2023217796A1
(en)
|
2022-05-10 |
2023-11-16 |
Miltenyi Biotec B.V. & Co. KG |
Compositions comprising il-15, il-15 receptor alpha and the intracellular signaling domain of cd2 for immune cell therapy
|
|
US20250339464A1
(en)
|
2022-05-16 |
2025-11-06 |
Miltenyi Biotec B.V. & Co. KG |
Endogenous signaling molecule activating chimeric antigen receptors and methods of generation thereof
|
|
EP4342488A1
(en)
|
2022-09-26 |
2024-03-27 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptor specific for folate receptor 1
|
|
WO2024078995A1
(en)
|
2022-10-15 |
2024-04-18 |
Miltenyi Biotec B.V. & Co. KG |
Transduction of gammadelta t cells with pseudotyped retroviral vectors
|
|
CN120548367A
(zh)
|
2022-11-18 |
2025-08-26 |
波士顿大学董事会 |
自复制rna及其用途
|
|
EP4471067A1
(en)
|
2023-06-01 |
2024-12-04 |
Miltenyi Biotec B.V. & Co. KG |
A chemically inducible heterodimerizing system and a method for generation thereof
|
|
WO2025008108A1
(en)
|
2023-07-06 |
2025-01-09 |
Miltenyi Biotec B.V. & Co. KG |
Immune cell expressing chimeric antigen receptor and transgenic t cell receptor
|
|
EP4545963A1
(en)
|
2023-10-26 |
2025-04-30 |
Miltenyi Biotec B.V. & Co. KG |
Method for selecting antigen recognizing moieties having specificity for a target structure
|
|
WO2025224123A1
(en)
|
2024-04-25 |
2025-10-30 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptors specific for fibroblast activation protein
|
|
WO2025252325A1
(en)
|
2024-06-06 |
2025-12-11 |
Miltenyi Biotec B.V. & Co. KG |
A human protein scaffold library based on the pdz3 domain of the tight junction protein zo-1
|
|
WO2025252326A1
(en)
|
2024-06-06 |
2025-12-11 |
Miltenyi Biotec B.V. & Co. KG |
A human protein scaffold library based on the n-terminal domain of human fact complex subunit ssrp1
|